ophthalmology Archives - Page 4 of 13 -

Twin late-stage trials of Roche’s ophthalmology drug faricimab have hit the mark in “wet” age-related macular degeneration trial,

Roche targets wet AMD with faricimab and its 16-week regimen

https://pharmaphorum.com/news/faricimab/

News/ News/ R&D

Roche set to file ophthalmology drug faricimab in DME

Richard Staines faricimab, Novartis, ophthalmology, Roche 0 Comment

Roche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody

Roche set to file ophthalmology drug faricimab in DME

https://pharmaphorum.com/news/roche-set-to-file-ophthalmology-drug-faricimab-in-dme/

Digital/ News/ News

Novartis signs ophthalmology AI deal with RetinAI

Richard Staines digital, Novartis, ophthalmology, RetinAI Medical 0 Comment

Novartis has signed a multi-year agreement with RetinAI, which will see the companies work together to use artificial

Novartis signs ophthalmology AI deal with RetinAI

https://pharmaphorum.com/news/novartis-signs-ophthalmology-ai-d/

News/ News/ R&D

Janssen adds Hemera’s AMD gene therapy to pipeline

Richard Staines Hemera, Janssen, Johnson & Johnson, M&A, ophthalmology, R&D 0 Comment

Johnson & Johnson’s pharma unit Janssen has bought rights to an investigational gene therapy for a severe form

Janssen adds Hemera’s AMD gene therapy to pipeline

https://pharmaphorum.com/news/janssen-adds-hemeras-amd-gene-therapy-to-ophthalmology-pipeline/

MyTherapy Novartis - See What's Next (002)

Digital/ News/ News

Novartis taps smartpatient for app to support wet AMD patients

Phil Taylor app, Beovu, digital, digital health, Lucentis, Novartis, ophthalmology, smartpatient, wet AMD 0 Comment

German digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet

Novartis taps smartpatient for app to support wet AMD patients

https://pharmaphorum.com/news/novartis-taps-smartpatient-for-app-to-support-wet-amd-patients/

Market Access/ News/ News

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

Richard Staines Biogen, biosimilars, market access, Novartis, ophthalmology, Samsung Bioepis 0 Comment

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

https://pharmaphorum.com/news/novartis-lucentis-could-face-biosimilar-competition/

News/ News/ R&D/ Top stories

Novartis keeps a close eye on gene therapy with Vedere Bio buy

Phil Taylor gene therapy, M&A, Novartis, ophthalmology, Vedere Bio 0 Comment

Already a major player in gene therapy, Novartis has swooped on US startup Vedere Bio in a $280

Novartis keeps a close eye on gene therapy with Vedere Bio buy

https://pharmaphorum.com/news/novartis-keeps-a-close-eye-on-gene-therapy-with-vedere-bio-buy/

News/ News/ R&D

SparingVision raises €44.5m for retinitis pigmentosa gene therapy

Richard Staines Funding, ophthalmology, Oxford Biomedica, R&D, Sanofi, SparingVision 0 Comment

French biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare

SparingVision raises €44.5m for retinitis pigmentosa gene therapy

https://pharmaphorum.com/news/sparingvision-raises-44-5-million-euros-for-retinitis-pigmentosa-gene-therapy/

News

Takeda to make $200m loss after Novartis’ dry-eye drug hits trouble in Europe

Richard Staines Novartis, ophthalmology, regulation, Shire, Takeda, Xiidra 0 Comment

Novartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing

Takeda to make $200m loss after Novartis’ dry-eye drug hits trouble in Europe

https://pharmaphorum.com/news/takeda-to-make-200m-loss-after-novartis-dry-eye-drug-hits-trouble-in-europe/

Trending

ophthalmology

Login